Date: 2015-08-24
Type of information: Nomination
Compound:
Company: Halozyme Therapeutics (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 24, 2015, Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, named Michael J. LaBarre, Ph.D. as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. The move broadens Dr. LaBarre\'s responsibilities to include research and development of early pipeline assets, in addition to his role managing product development and ENHANZE™ platform partnerships. Dr. LaBarre\'s career comprises more than 2 decades of biotech drug discovery and development experience, including work on successful approvals of commercial therapies such as Rituxan™. Prior to joining Halozyme in 2008, he served as vice president, product development at Paramount BioSciences LLC; director, analytical and protein biochemistry, discovery research at Biogen Idec; and director analytical and formulation sciences, research and development at IDEC Pharmaceuticals. He earned his B.S. in Chemistry from Southampton College of Long Island University and Ph.D. in Bioinorganic Chemistry from the University of Arizona.
Financial terms:
Latest news:
